Effectiveness and Safety of Novel Nutraceutical Formulation Added to Ezetimibe in Statin-Intolerant Hypercholesterolemic Subjects with Moderate-to-High Cardiovascular Risk.
Anticholesteremic Agents
/ therapeutic use
Cardiovascular Diseases
/ drug therapy
Dietary Supplements
Drug Therapy, Combination
Ezetimibe
/ therapeutic use
Heart Disease Risk Factors
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ adverse effects
Lipids
/ blood
Risk Factors
Treatment Outcome
LDL cholesterol
Monacolin-K
bioavailability
cardiovascular risk
ezetimibe
nutraceutical compounds
quercetin
resveratrol
statin intolerance
Journal
Journal of medicinal food
ISSN: 1557-7600
Titre abrégé: J Med Food
Pays: United States
ID NLM: 9812512
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
pubmed:
28
5
2020
medline:
22
4
2021
entrez:
28
5
2020
Statut:
ppublish
Résumé
The effectiveness of statins in the primary and secondary prevention of cardiovascular (CV) diseases has been widely proven. However, the onset of adverse events associated with their use prevents to achieve the therapeutic targets recommended by the guidelines (GL) for the management of dyslipidemia. In the event of statin intolerance, the GL recommend to use bile acid sequestrants, fibrates, and ezetimibe in monotherapy, but their benefits in improving lipid pattern are quite modest. This study aims at evaluating the effectiveness and safety of a nutraceutical compound (NC) associated with ezetimibe (EZE) on the lipid profile in statin-intolerant patients with moderate-to-high CV risk. Ninety-six statin-intolerant hypertensive and hypercholesterolemic subjects treated pharmacologically with EZE 10 mg daily were randomized in open label (
Identifiants
pubmed: 32456525
doi: 10.1089/jmf.2020.0019
doi:
Substances chimiques
Anticholesteremic Agents
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Lipids
0
Ezetimibe
EOR26LQQ24
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM